ENTITY
Jacobio Pharmaceuticals

Jacobio Pharmaceuticals (1167 HK)

83
Analysis
Health Care • China
Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the in-house discovery and development of innovative oncology therapies, focusing on "undruggable" targets in key oncogenic pathways. They leverage their Induced Allosteric Molecule Discovery Platform and iADC Platform to develop novel drugs, including clinical-stage candidates like Glecirasib (KRAS G12C inhibitor) and Sitneprotafib (SHP2 inhibitor) for various solid tumors. The company was founded in 2015 and is headquartered in Beijing, China.
more
•21 Oct 2020 02:00

Jacobio Pharma: Focus on Novel Targets

An in-depth overview of the proposed listing of Jacobio Pharmaceuticals using a framework that touches on the science, market opportunity,...

Share
•14 Oct 2020 09:57

Jacobio (加科思药业) Pre-IPO: Right Team but Long Time to Market

Jacobio is a clinical stage China biotech company with a focus on small molecule oncology drugs. The company was founded by Dr. Wang, co-founder of...

Logo
638 Views
Share
x